Filter by:
  • Trial Status
  • Trial Phase
  • Age
  • Sex
  • Location

    location

    Clear All

About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

370533 studies
in
219 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 04/16/2021.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 04/16/2021.
Displaying: 216,978 trials in your specialties ()
View trials across your selected specialties

Pembrolizumab TX-naive Distant Mets Melanoma and Use of (C11-AMT) PET at Baseline as Imaging Biomarker

  • Status
    Active, not recruiting
  • Phase
    Phase 2
  • Condition
    Melanoma
View Full Trial
INTERVENTION

Diagnostic Test: FDG PET/CT scan, Diagnostic Test: C11-AMT PET scan, Drug: Pembrolizumab, Diagnostic Test: FDG PET/CT scan with IV contrast

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States

Brief Summary

Explore association between intensity of C11-AMT PET at baseline, as measured by mean standardized uptake value (SUVmax at each lesion), total tumor metabolic volume, measurement of intra-tumoral and inter-lesional heterogeneity), with objective response rate (ORR) at 12 weeks (as defined via RECIST 1.1) to pembrolizumab in patients with treatment-naïve metastatic melanoma.

A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma

  • Status
    Active, not recruiting
  • Phase
    Phase 3
  • Condition
    Melanoma
View Full Trial
INTERVENTION

Drug: Cobimetinib, Drug: Vemurafenib, Drug: Atezolizumab, Drug: Atezolizumab Placebo, Drug: Vemurafenib Placebo

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

UZ Leuven Gasthuisberg, Leuven, Belgium

Brief Summary

This is a Phase III, double-blinded, placebo-controlled, randomized, multicenter study designed to evaluate the efficacy, safety, and pharmacokinetics of atezolizumab + cobimetinib + vemurafenib compared with placebo + cobimetinib + vemurafenib in patients with previously untreated BRAFv600 mutation-positive metastatic or unresectable locally advanced melanoma.

A Dose Escalation Phase I Study Of Human- Recombinant Bone Morphogenetic Protein 4 Administrated Via CED In GBM Patients

  • Status
    Active, not recruiting
  • Phase
    Phase 1
  • Condition
    Glioblastoma
View Full Trial
INTERVENTION

Drug: hrBMP4

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

Brief Summary

The purpose of the study is to evaluate the feasibility and safety of intra-tumor and interstitial therapy with hBMP4 in increasing doses in patients with progressive and/or multiple recurrent Glioblastoma multiforme (GBM).

Empagliflozin Impact on Hemodynamics in Patients With Heart Failure

  • Status
    Active, not recruiting
  • Phase
    Phase 4
  • Condition
    Heart Failure
View Full Trial
INTERVENTION

Drug: Empagliflozin 10Mg Tab, Drug: Placebo Oral Tablet

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

University of Southern California, Los Angeles, California, United States

Brief Summary

The primary purpose of this trial is to evaluate the impact of empagliflozin, as compared with placebo, on hemodynamic parameters (pulmonary artery diastolic pressure) in patients with heart failure (reduced or preserved ejection fraction, ischemic or non-ischemic etiology) who already have a CardioMEMs device implanted for non-study related clinical reasons.

Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma

  • Status
    Active, not recruiting
  • Phase
    Phase 2
  • Condition
    Biliary Carcinoma, Gall Bladder Carcinoma, Gastrointestinal Tumor...
View Full Trial
INTERVENTION

Drug: Cisplatin, Drug: Gemcitabine, Drug: Copanlisib

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Brief Summary

The purpose of this study is to see if an experimental drug, called copanlisib is effective and safe in treating adult participants with cholangiocarcinoma, when used in combination with gemcitabine and cisplatin.

Wide Excision Alone as Treatment for Ductal Carcinoma in Situ of The Breast

  • Status
    Active, not recruiting
  • Phase
    Phase 2
  • Condition
    Ductal Carcinoma in Situ of the Breast
View Full Trial
INTERVENTION

Other: Observation

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Brief Summary

The purpose of this study is to determine if wide excision (surgical removal) alone is adequate treatment for small, grade 1 or 2 ductal carcinoma in situ (DCIS) of the breast.

A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors

  • Status
    Active, not recruiting
  • Phase
    Phase 1
  • Condition
    Advanced Solid Tumors
View Full Trial
INTERVENTION

Drug: Venetoclax, Drug: Rovalpituzumab Tesirine, Drug: ABBV-181

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Moore UC San Diego Cancer Center /ID# 157374, La Jolla, California, United States

Brief Summary

This is an open-label, Phase I, dose-escalation study to determine the recommended Phase 2 dose (RPTD), maximum tolerated dose (MTD), and evaluate the safety and pharmacokinetic (PK) profile of budigalimab. This study will also evaluate the safety and tolerability of budigalimab in combination with Rovalpituzumab Tesirine and budigalimab in combination with venetoclax. The study will consist of 3 parts: budigalimab monotherapy dose escalation and expansion, budigalimab in combination with Rovalpituzumab Tesirine and budigalimab in combination with venetoclax.

A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors ( PIVOT-02 )

  • Status
    Active, not recruiting
  • Phase
    Phase 1 Phase 2
  • Condition
    Colorectal Cancer, Metastatic Breast Cancer, Renal Cell Carcinoma...
View Full Trial
INTERVENTION

Drug: Combination of NKTR-214 + nivolumab, Drug: Combination of NKTR-214 + nivolumab, Drug: Combination of NKTR-214 + nivolumab + ipilimumab, Drug: Combination of NKTR-214 + nivolumab + ipilimumab

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Local Institution - La Jolla, La Jolla, California, United States

Brief Summary

In this four-part study, NKTR-214 will be administered in combination with nivolumab in Part 1, in combination with nivolumab with or without various chemotherapies in Part 2, and with nivolumab and ipilimumab in Parts 3 & 4. In Part 1, the Recommended Phase 2 Dose (RP2D) of NKTR-214 in combination with nivolumab will be determined. In Part 2, NKTR-214 with nivolumab at the RP2D will be evaluated as first-line therapy and/or as second or third line therapy in select patients with Melanoma, Renal Cell Carcinoma (RCC), Non-Small Cell Lung Cancer (NSCLC), Urothelial Carcinoma (UC), metastatic Breast Cancer (mBC) and Colorectal Cancer (CRC). In addition, in Part 2, the RP2D of NKTR-214 with nivolumab and various chemotherapies and regimens in select cohorts of NSCLC patients will be determined. In Part 3, several different regimens of the triplet combination of NKTR-214 plus nivolumab and ipilimumab will be evaluated in select patients with RCC, NSCLC, Melanoma, and UC. In Part 4, the safety and efficacy of the triplet combination will be evaluated further in select patients with RCC, NSCLC, Melanoma and UC.

A Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Participants With Crohn's Disease

  • Status
    Active, not recruiting
  • Phase
    Phase 2
  • Condition
    Crohn's Disease (CD)
View Full Trial
INTERVENTION

Drug: ABT-494

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Moore UC San Diego Cancer Center /ID# 150041, La Jolla, California, United States

Brief Summary

This is a open-label extension (OLE) study designed to evaluate the long-term efficacy, safety, and tolerability of Upadacitinib (ABT-494).

XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma

  • Status
    Active, not recruiting
  • Phase
    Phase 1
  • Condition
    Melanoma, Skin Cancer
View Full Trial
INTERVENTION

Drug: XL888, Drug: Vemurafenib, Drug: Cobimetinib

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Brief Summary

The main purpose of this study is to determine the maximum tolerated dose (MTD) and recommended phase II dose (RP2D) of XL888 when administered orally with vemurafenib plus cobimetinib in participants with BRAF V600 mutated melanoma and to evaluate the safety and tolerability of this combination.